Search results
12 lip 2024 · This guidance document provides recommendations to clinicians for treatment of infections caused by extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and difficult-to-treat Pseudomonas aeruginosa (DTR-P. aeruginosa).
- Infection Prevention & Control
IDSA/SHEA: Primer on Healthcare Epidemiology, Infection...
- Guideline Development Process
Because of the large number of clinical practice guidelines...
- Ebola
What is Ebola? Ebola virus disease is a severe illness that...
- Evaluation and Management Services
Dr. Timothy Sullivan, Vice Chair of IDSA’s Coding & Payment...
- Bio-Preparedness Workforce Pilot
On Thursday, June 15, in Washington, D.C., Axios health care...
- Lyme Disease
IDSA engages in advocacy efforts that support better Lyme...
- ID Match
The IDSA ID Match Resolution provides guiding principles for...
- Hepatitis C
Viral hepatitis is a silent epidemic. According to the...
- Infection Prevention & Control
19 kwi 2022 · For this guidance document, ESBL-E will refer to presumed or confirmed ESBL-producing E. coli, K. pneumoniae, K. oxytoca, or P. mirabilis. Treatment recommendations for ESBL-E infections listed below assume that in vitro activity of preferred and alternative antibiotics has been demonstrated.
Find and save your easy, simple, healthy recipes and meal ideas for you and your entire family. We have the best chicken dinners, crockpot recipes, tried-and-true classics, sheet-pan meals ...
5 paź 2024 · Current IDSA guidelines recommend against empiric use of piperacillin-tazobactam for ESBL-E infections A study demonstrated a 12% vs 4% 30 day mortality between Zosyn and Meropenem when used for ESBL-E bloodstream infections. 12 Complications. Inadequate empiric therapy can lead to treatment delays and worse outcomes.
18 kwi 2022 · Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
27 paź 2020 · This guidance document provides recommendations for the treatment of infections caused by extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa).
18 lip 2023 · Guidance is presented in the form of answers to a series of clinical questions for each pathogen. Although brief descriptions of notable clinical trials, resistance mechanisms, and antimicrobial susceptibility testing (AST) methods are included, the document does not provide a comprehensive review of these topics.
